These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9658641)

  • 1. [Current status of p53 tumor suppressor gene as a possible molecular marker of cancer of the prostate].
    Peña González JA; Morote Robles J; de Torres Ramírez IM; Martínez Cuenca E
    Actas Urol Esp; 1998 Apr; 22(4):279-90. PubMed ID: 9658641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression.
    Fan R; Kumaravel TS; Jalali F; Marrano P; Squire JA; Bristow RG
    Cancer Res; 2004 Dec; 64(23):8526-33. PubMed ID: 15574758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumour suppressor gene.
    Steele RJ; Thompson AM; Hall PA; Lane DP
    Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.
    Spurgers KB; Coombes KR; Meyn RE; Gold DL; Logothetis CJ; Johnson TJ; McDonnell TJ
    Oncogene; 2004 Mar; 23(9):1712-23. PubMed ID: 14647426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
    Salnikow K; Costa M; Figg WD; Blagosklonny MV
    Cancer Res; 2000 Oct; 60(20):5630-4. PubMed ID: 11059752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
    Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
    Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation.
    Scott SL; Earle JD; Gumerlock PH
    Cancer Res; 2003 Nov; 63(21):7190-6. PubMed ID: 14612513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Environmental carcinogens and p53 gene mutation].
    Xu Z; Jin Y
    Wei Sheng Yan Jiu; 2004 Mar; 33(2):239-43. PubMed ID: 15209018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of p53 are common in early stage prostate cancer.
    Downing SR; Russell PJ; Jackson P
    Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
    Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
    Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
    Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M
    Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
    Tang DG; Li L; Chopra DP; Porter AT
    Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
    Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV
    Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells.
    Choi MS; Oh JH; Kim SM; Jung HY; Yoo HS; Lee YM; Moon DC; Han SB; Hong JT
    Int J Oncol; 2009 May; 34(5):1221-30. PubMed ID: 19360335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.